Wegovy vs Mounjaro Real-World Evidence Comparison

What the Key Trials Actually Show

Semaglutide 2.4 mg and tirzepatide were never tested head-to-head in a single randomized controlled trial, so comparing them requires careful reading of parallel trials and real-world data. The numbers are still striking.

STEP-1: The Wegovy Benchmark

In STEP-1 (N=1,961), 68 weeks of subcutaneous semaglutide 2.4 mg once weekly produced a mean body-weight loss of 14.9% versus 2.4% with placebo (P<0.001) [1]. Roughly 86% of participants lost at least 5% of body weight, and 70% lost at least 10%. These were adults without type 2 diabetes, which matters because metabolic status affects GLP-1 drug response.

The trial also reported meaningful reductions in waist circumference (mean 13.54 cm) and systolic blood pressure (mean 6.16 mmHg). Gastrointestinal adverse events led to discontinuation in about 7% of the semaglutide group [1].

SURMOUNT-1: The Mounjaro Benchmark

SURMOUNT-1 (N=2,539) tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly for 72 weeks in adults without type 2 diabetes [2]. The 15 mg arm produced a 20.9% mean weight loss versus 3.1% with placebo. The 10 mg arm achieved 19.5%, and even the lowest 5 mg dose delivered 15.0%, outpacing the semaglutide STEP-1 result at nearly every dose level [2].

At tirzepatide 15 mg, 57% of participants lost at least 20% of body weight, a threshold that 32% of Wegovy participants in STEP-1 crossed. That difference in the proportion reaching 20% weight loss is one of the most clinically meaningful contrasts between the two drugs.

Why Direct Comparison Is Complicated

Trials differ in duration (68 vs 72 weeks), baseline BMI, and run-in periods. SURPASS-2, which compared tirzepatide directly against semaglutide 1 mg (not 2.4 mg) in patients with type 2 diabetes, showed tirzepatide 15 mg achieving 5.5 percentage points more weight loss than semaglutide 1 mg at 40 weeks (P<0.001) [3]. That finding supports tirzepatide superiority but cannot be extrapolated cleanly to the Wegovy 2.4 mg dose.

Real-World Evidence: What Happens Outside Trials

Randomized trials enroll highly selected patients. Real-world studies capture the messier reality of commercial insurance, dose escalation failures, and adherence gaps.

The 2024 Epic Cosmos Cohort

A 2024 analysis published in JAMA Internal Medicine used Epic Cosmos data from over 18,000 adults prescribed either semaglutide or tirzepatide for weight management in US clinical practice [4]. At 12 months, tirzepatide users lost a mean of 15.3% of body weight versus 8.3% for semaglutide users, a difference of 7.0 percentage points after propensity-score adjustment. Discontinuation rates were similar between the two drugs at 6 months (about 40% for both), but tirzepatide users who stayed on therapy lost meaningfully more weight through month 12.

The authors noted that real-world dose escalation was slower than in trials, which likely explains why absolute weight loss in both groups fell below trial benchmarks [4].

Insurance Claims and Pharmacy Refill Data

A 2023 analysis of commercial insurance claims (N=9,077 matched pairs) found that tirzepatide was associated with greater weight-related comorbidity improvement at 6 months compared with semaglutide 1 mg or 2 mg doses [5]. A1C reductions and blood-pressure improvements both tracked with the greater weight loss in tirzepatide users.

Persistence data from pharmacy refill records suggest roughly 50 to 60% of patients on either drug fill a 90-day supply at 6 months, with no statistically significant difference between the two agents in most datasets reviewed.

The GIP Mechanism: Why Tirzepatide May Win on Weight

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. The GIP receptor pathway appears to amplify the weight-loss signal in adipose tissue independently of GLP-1 activity [6]. A 2023 mechanistic study in Nature Metabolism showed that GIP receptor agonism reduces adipocyte lipid storage and potentiates GLP-1-mediated satiety in rodent and human tissue models. That synergistic receptor action is the leading pharmacological explanation for why tirzepatide consistently outperforms semaglutide on weight loss even at doses that are not fully maximized.

Cardiovascular Outcomes: Where Wegovy Has a Clear Edge

Weight loss is not the only reason patients take these drugs. Cardiovascular risk reduction matters, and the data here favor Wegovy for now.

The SELECT Trial

The SELECT cardiovascular outcomes trial (N=17,604) showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo over a mean follow-up of 34.2 months in adults with established cardiovascular disease and overweight or obesity (but without diabetes) [7]. The hazard ratio was 0.80 (95% CI 0.72 to 0.90, P<0.001). This trial led the FDA to update Wegovy's label to include a cardiovascular risk-reduction indication in March 2024.

As of mid-2025, tirzepatide does not have an equivalent cardiovascular outcomes trial in people without diabetes. The SURPASS-CVOT trial compared tirzepatide against insulin degludec in type 2 diabetes patients and showed non-inferior cardiovascular safety but did not demonstrate superiority [8].

What That Means Clinically

For a patient with a prior myocardial infarction or stroke who also needs weight management, Wegovy carries an FDA-recognized cardiovascular indication that tirzepatide does not yet match in that population. The American Heart Association's 2023 obesity and cardiovascular disease guideline cited SELECT-level data as the new standard for pharmacological intervention in that group [9].

Patients whose primary concern is maximum weight loss without a significant cardiovascular history have a different calculus.

Side Effect Profiles: More Similar Than Different

Both drugs share a class-level GI side-effect profile because both activate GLP-1 receptors in the gut.

Nausea, Vomiting, and Diarrhea

In STEP-1, nausea affected 44% of semaglutide participants versus 16% on placebo [1]. In SURMOUNT-1, nausea occurred in 31% of the tirzepatide 15 mg group [2]. That lower absolute rate for tirzepatide may reflect its slower gastric-emptying curve at the starting dose or differences in trial design, but head-to-head GI tolerability comparisons remain limited.

Vomiting rates: approximately 24% with semaglutide 2.4 mg in STEP-1 versus 18% with tirzepatide 15 mg in SURMOUNT-1. These numbers come from different trials and should be interpreted with caution.

Injection Site and Administration

Both drugs are once-weekly subcutaneous injections. Wegovy uses a single-dose prefilled pen; tirzepatide (Mounjaro/Zepbound) uses a similar autoinjector. Neither requires reconstitution, which simplifies home administration compared with older injectable peptides.

Pancreatitis and Thyroid Risk

The FDA label for both agents carries a warning about thyroid C-cell tumors based on rodent data, and neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma or MEN2 [10]. Acute pancreatitis is listed as a risk for the GLP-1 class broadly. Neither drug has shown a statistically significant increase in pancreatitis incidence in their large outcome trials.

Switching from Wegovy to Mounjaro: A Clinical Guide

Patients switch for several reasons: inadequate weight loss on semaglutide, insurance formulary changes, supply chain issues, or a preference for the GIP-plus-GLP-1 mechanism.

Starting Dose When Switching

The standard approach, consistent with HealthRX clinical protocols and supported by emerging prescriber guidance, is to restart tirzepatide at the 2.5 mg weekly starting dose regardless of what semaglutide dose the patient was on. GIP receptor agonism introduces a new pharmacological dimension, and GI adverse events can recur even in patients who tolerated semaglutide well at higher doses.

A 2024 letter to the editor in Obesity Medicine described 42 patients switching from semaglutide 2.4 mg to tirzepatide: 78% completed dose escalation to at least 10 mg without requiring a dose reduction, and mean weight loss at 6 months post-switch was an additional 6.2% of body weight [11].

Washout Period

No washout period is required. Tirzepatide can begin the week after the last semaglutide dose because both drugs have approximately 7-day half-lives and the mechanism overlap (GLP-1 receptor agonism) does not create a pharmacological collision. Starting tirzepatide immediately after stopping semaglutide avoids a return of appetite in the gap week.

Monitoring After Switch

• Recheck fasting glucose and A1C at 12 weeks post-switch in patients with prediabetes or type 2 diabetes, as tirzepatide's GIP component produces additional glucose lowering beyond semaglutide.
• Recheck blood pressure at 8 weeks, as weight loss acceleration may require antihypertensive dose adjustment.
• Reassess GI symptoms weekly for the first 4 weeks; nausea recurrence is the most common complaint in switchers even with prior GLP-1 tolerance.

Who Should Not Switch

Patients who achieved 15% or more body-weight loss on semaglutide 2.4 mg and have stable, well-tolerated therapy may not benefit from switching. The marginal gain in weight loss must be weighed against restarting a dose-escalation ladder, potential GI adverse events, and any formulary cost differential.

Cost, Coverage, and Access

List price for both Wegovy and Zepbound (the weight-management branded form of tirzepatide) runs approximately $900 to $1,300 per month in the United States without insurance [12]. Manufacturer savings cards can reduce out-of-pocket cost to as low as $25/month for commercially insured patients who qualify, though these offers exclude Medicare and Medicaid beneficiaries.

Medicare Part D coverage for anti-obesity medications has been excluded by statute since 2003, though proposed rule changes discussed in 2024 may expand coverage in future years. Medicaid coverage varies by state.

Compounded semaglutide and tirzepatide have been widely available during periods of FDA-listed drug shortages. The FDA removed semaglutide (Wegovy formulation) from the shortage list in early 2024 and tirzepatide in late 2024, which has prompted enforcement action against compounding pharmacies producing copies outside 503A/503B exemptions [13].

How to Choose: A Decision Framework

The right drug depends on the patient's clinical profile, not the drug with the higher average weight-loss percentage.

Choose Wegovy (semaglutide 2.4 mg) if:

• The patient has established cardiovascular disease and needs the SELECT-level MACE reduction evidence.
• The patient has already achieved good results on a lower semaglutide dose and is stepping up.
• Insurance coverage is confirmed for Wegovy but not Zepbound.

Choose Mounjaro/Zepbound (tirzepatide) if:

• Maximum weight loss is the primary goal and cardiovascular history is not a limiting factor.
• The patient has type 2 diabetes and needs dual glucose-lowering plus weight management.
• Semaglutide was well tolerated but weight-loss plateau was reached before 15% body-weight reduction.

Defer the decision if:

• The patient has not yet tried a GLP-1 agent; start with whichever drug is covered and available.
• Active GI disease, gastroparesis, or a history of pancreatitis needs specialist clearance before either drug.

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states that drug selection should account for "comorbidity profile, contraindications, patient preference, and medication access" rather than a single efficacy metric [14].